Ginger Johnson

Company: Lumanity

Job title: President

Seminars:

Panel Discussion: Starting with the End in Mind: Strategic Access Planning at the Earliest Stages for CNS Therapeutics 8:30 am

CNS drugs face uniquely complex access hurdles: diagnostic ambiguity, subjective endpoints, societal stigma, infrastructure gaps, and payer scepticism toward psychiatric or neurodegenerative indications Market access strategy cannot wait until Phase 3 – strategy and decisions need to be made at the earliest stages of development to lock in value later Key Questions: Why is it…Read more

day: Conference Day One